GVHD
GVHD
Advertisement
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Best Practices | March 8, 2023
Many patients don't have a plan for returning to work. You can help them make a plan and adapt to changes along the way.
Read More
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Best Practices | March 8, 2023
Do you know how to assess for gut GVHD? This article covers assessment, pathobiology, and staging.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Best Practices | March 8, 2023
In patients with GVHD, some forms of grief are expected and accepted, yet others go unrecognized.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Best Practices | March 8, 2023
Using these 3 strategies, you can build your resiliency to benefit yourself and your patients.
Dustin SamplesConferences | February 21, 2023
Continuous intravenous tacrolimus administration can be logistically challenging. Can intermittent dosing work as well?
Dustin SamplesGVHD | February 16, 2023
Vascular access events caused most patients to discontinue treatment. Does catheter type affect event frequency?
Dustin SamplesGVHD | February 16, 2023
Can extracorporeal photopheresis treat acute graft-versus-host disease when the disease has become steroid dependent?
Dustin SamplesGVHD | February 15, 2023
The accepted belief is that late-onset acute GVHD is less severe, but one study demonstrated the opposite.
Patrick DalyGVHD | December 22, 2022
Different radiotherapy doses in allogeneic HCT conditioning had no apparent impact on the rate of acute GVHD.
Patrick DalyGVHD | December 22, 2022
Authors observed that ocular graft-versus-host disease usually developed after a history of systemic disease.
Patrick DalyGVHD | December 22, 2022
A study found fecal microbiome dysbiosis accompanied the onset of gastrointestinal graft-versus-host disease.
Patrick DalyGVHD | December 22, 2022
BCG vaccination at birth was associated with increased risk of acute GVHD after HCT in pediatric patients.
Patrick DalyGVHD | December 20, 2022
Vitamin D Deficiency before HSCT was associated with increased rate of aGVHD in patients with thalassemia major.
Patrick DalyGVHD | December 20, 2022
Higher tacrolimus pharmacokinetic variability had a greater risk of aGVHD that rose alongside concentration variability.
Patrick DalyGVHD | December 20, 2022
defibrotide added to standard-of-care graft-versus-host disease prophylaxis appeared to improve the rate of acute GVHD.
Patrick DalyGVHD | December 20, 2022
FEV1/FVC and PEF/pred could identify patients with higher risk for pulmonary chronic graft-versus-host disease before HSCT.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | December 7, 2022
Elaine DeMeyer describes cardiovascular toxicities related to GVHD and what nurses should look for to evaluate risk.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | December 7, 2022
Elaine DeMeyer, RN, MSN, describes cGVHD phenotypes presenting in the lungs, including BOS and COP.
Patrick DalyGVHD | December 7, 2022
Real-world data showed that ruxolitinib was effective in a population of heavily pretreated patients with cGVHD.
Patrick DalyGVHD | December 7, 2022
Vedolizumab was safe and effective for GI aGVHD treatment, although its efficacy as GVHD prophylaxis was unclear.
Advertisement
Advertisement
Advertisement